U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H21ClN4O5
Molecular Weight 420.847
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THEOFIBRATE

SMILES

CN1C2=C(N(CCOC(=O)C(C)(C)OC3=CC=C(Cl)C=C3)C=N2)C(=O)N(C)C1=O

InChI

InChIKey=KYAKGJDISSNVPZ-UHFFFAOYSA-N
InChI=1S/C19H21ClN4O5/c1-19(2,29-13-7-5-12(20)6-8-13)17(26)28-10-9-24-11-21-15-14(24)16(25)23(4)18(27)22(15)3/h5-8,11H,9-10H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C19H21ClN4O5
Molecular Weight 420.847
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/theofibrate.html | https://www.ncbi.nlm.nih.gov/pubmed/7045566 | https://www.drugs.com/international/etofylline-clofibrate.html | https://www.ncbi.nlm.nih.gov/pubmed/7045566

Theofibrate (Etofylline clofibrate, trade name Duolip) is the clofibric acid ester of theophylline, used for the treatment of hyperlipoproteinaemia with elevated triglycerides and cholesterol. The low dose of Etophylline clofibrate (750mg) has a similar lipid-lowering effect as pure clofibrate (1500mg), probably due to a synergistic hypolipidemic effect with theophylline, which has no lipid-lowering effect per se. Secondly, etophylline clofibrate substantially decreases platelet aggregability and plasma viscosity, properties which may be desirable in the prevention of coronary heart disease (CHD). Finally, etophylline clofibrate is clearly a less potent inducer of peroxisomal proliferation in the rat liver than clofibrate, bezafibrate or fenofibrate. Theofibrate increases lipoprotein lipase activity to promote the conversion of Very low-density lipoprotein (VLDL) to Low-density lipoprotein (LDL), and hence reduce the level of VLDL.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Duolip forte

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effect of etofylline clofibrate on experimental thrombus formation and prostacyclin activation.
1986 Sep
Patents

Patents

Sample Use Guides

500 - 750 mg once daily for 12-16 weeks
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:21:03 GMT 2023
Edited
by admin
on Fri Dec 15 15:21:03 GMT 2023
Record UNII
14UH1JQP6L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THEOFIBRATE
MI   USAN  
USAN  
Official Name English
ETOFYLLINE CLOFIBRATE [MART.]
Common Name English
ML-1024
Code English
CLOFIBRATE ETOFYLLINE
Common Name English
etofylline clofibrate [INN]
Common Name English
NSC-234348
Code English
DUOLIP
Brand Name English
PROPANOIC ACID, 2-(4-CHLOROPHENOXY)-2-METHYL-, 2-(1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-7H-PURIN-7-YL)ETHYL ESTER
Common Name English
ETOFYLLINE CLOFIBRATE
INN   MART.   WHO-DD  
INN  
Official Name English
Etofylline clofibrate [WHO-DD]
Common Name English
2-(P-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID, ESTER WITH 7-(2-HYDROXYETHYL)THEOPHYLLINE
Common Name English
THEOFIBRATE [USAN]
Common Name English
THEOFIBRATE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98150
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
Code System Code Type Description
DRUG CENTRAL
1108
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
RXCUI
236713
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C152583
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
SMS_ID
100000092279
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
ChEMBL
CHEMBL1318939
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
INN
4271
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
PUBCHEM
41109
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
CAS
54504-70-0
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
NSC
234348
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
EVMPD
SUB07325MIG
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
FDA UNII
14UH1JQP6L
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
MERCK INDEX
m10705
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
259-191-6
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
EPA CompTox
DTXSID0023032
Created by admin on Fri Dec 15 15:21:03 GMT 2023 , Edited by admin on Fri Dec 15 15:21:03 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY